Slingshot members are tracking this event:
Top-Line Data Expected in Q4 2017 for Aimmune's (AIMT) Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Feb 20, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3, Palisade, Top-line Data, Peanut Allergies